Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2016

01-01-2016 | Original Article

Imaging malignant melanoma with 18F-5-FPN

Authors: Hongyan Feng, Xiaotian Xia, Chongjiao Li, Yiling Song, Chunxia Qin, Qingyao Liu, Yongxue Zhang, Xiaoli Lan

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2016

Login to get access

Abstract

Purpose

Radiolabelled benzamides are attractive candidates for targeting melanoma because they bind to melanin and exhibit high tumour uptake and retention. 18F-5-Fluoro-N-(2-[diethylamino]ethyl)picolinamide (18F-5-FPN), a benzamide analogue, was prepared and its pharmacokinetics and binding affinity evaluated both in vitro and in vivo to assess its clinical potential in the diagnosis and staging of melanoma.

Methods

18F-5-FPN was prepared and purified. Its binding specificity was measured in vitro in two different melanoma cell lines, one pigmented (B16F10 cells) and one nonpigmented (A375m cells), and in vivo in mice xenografted with the same cell lines. Dynamic and static PET images using 18F-5-FPN were obtained in the tumour-bearing mice, and the static images were also compared with those acquired with 18F-FDG. PET imaging with 18F-5-FPN was also performed in B16F10 tumour-bearing mice with lung metastases.

Results

18F-5-FPN was successfully prepared with radiochemical yields of 5 – 10 %. Binding of 18F-5-FPN to B16F10 cells was much higher than to A375m cells. On dynamic PET imaging B16F10 tumours were visible about 1 min after injection of the tracer, and the uptake gradually increased over time. 18F-5-FPN was rapidly excreted via the kidneys. B16F10 tumours were clearly visible on static images acquired 1 and 2 h after injection, with high uptake values of 24.34 ± 6.32 %ID/g and 16.63 ± 5.41 %ID/g, respectively, in the biodistribution study (five mice). However, there was no visible uptake by A375m tumours. 18F-5-FPN and 18F-FDG PET imaging were compared in B16F10 tumour xenografts, and the tumour-to-background ratio of 18F-5-FPN was ten times higher than that of 18F-FDG (35.22 ± 7.02 vs. 3.29 ± 0.53, five mice). 18F-5-FPN PET imaging also detected simulated lung metastases measuring 1 – 2 mm.

Conclusion

18F-5-FPN specifically targeted melanin in vitro and in vivo with high retention and affinity and favourable pharmacokinetics. 18F-5-FPN may be an ideal molecular probe for melanoma diagnosis and staging.
Literature
1.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed
3.
Chen J, Shao R, Zhang XD, Chen C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine. 2013;8:2677–88.PubMedCentralCrossRefPubMed
4.
5.
Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545–80.CrossRefPubMed
6.
McIvor J, Siew T, Campbell A, McCarthy M. FDG PET in early stage cutaneous malignant melanoma. J Med Imaging Radiat Oncol. 2014;58:149–54.CrossRefPubMed
7.
Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014;23:11–6.CrossRefPubMed
8.
Keu KV, Iagaru AH. The clinical use of PET/CT in the evaluation of melanoma. Methods Mol Biol. 2014;1102:553–80.CrossRefPubMed
9.
Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, et al. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med. 2012;53:281–6.CrossRefPubMed
10.
Matzku S, Kirchgessner H, Schmid U, Temponi M, Ferrone S. Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med. 1989;30:390–7.PubMed
11.
Larson SM, Brown JP, Wright PW, Carrasquillo JA, Hellström I, Hellström KE. Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med. 1983;24:123–9.PubMed
12.
13.
Cheng Z, Zhang L, Graves E, Xiong Z, Dandekar M, Chen X, et al. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med. 2007;48:987–94.PubMedCentralCrossRefPubMed
14.
Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm. 2006;21:117–29.CrossRefPubMed
15.
Ito Y, Doi H, Tsuji H, Ishida-Yamamto A, Iizuka H. Malignant melanoma of the breast: N-isopropyl-p-(123) I-iodoamphetamine single photon emission computed tomography ((123) I-IMP SPECT) is useful for the detection of metastasis. J Dermatol. 2010;37:849–51.CrossRefPubMed
16.
Yoshimura M, Kanesaka N, Saito K, Koizumi K, Tokuuye K, Goto H. Diagnosis of uveal malignant melanoma by a new semiquantitative assessment of N-isopropyl-p-[123I]-iodoamphetamine. Jpn J Ophthalmol. 2011;55:148–54.CrossRefPubMed
17.
Cachin F, Miot-Noirault E, Gillet B, Isnardi V, Labeille B, Payoux P, et al. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial. J Nucl Med. 2014;55:15–22.CrossRefPubMed
18.
Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, et al. Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Res. 2010;70:4045–53.PubMedCentralCrossRefPubMed
19.
Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A, et al. Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med. 2009;50:1692–9.PubMedCentralCrossRefPubMed
20.
Denoyer D, Potdevin T, Roselt P, Neels OC, Kirby L, Greguric I, et al. Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med. 2011;52:115–22.CrossRefPubMed
21.
Garg S, Kothari K, Thopate SR, Doke AK, Garg PK. Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem. 2009;20:583–90.PubMedCentralCrossRefPubMed
22.
Denoyer D, Greguric I, Roselt P, Neels OC, Aide N, Taylor SR, et al. High-contrast PET of melanoma using 18F-MEL050, a selective probe for melanin with predominantly renal clearance. J Nucl Med. 2010;51:441–7.CrossRefPubMed
23.
Greguric I, Taylor SR, Denoyer D, Ballantyne P, Berghofer P, Roselt P, et al. Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. J Med Chem. 2009;52:5299–302.CrossRefPubMed
24.
Liu H, Liu S, Miao Z, Deng Z, Shen B, Hong X, et al. Development of 18F-labeled picolinamide probes for PET imaging of malignant melanoma. J Med Chem. 2013;56:895–901.PubMedCentralCrossRefPubMed
25.
Wang L, Zhu J, Liang X, Niu M, Wu X, Kao CM, et al. Performance evaluation of the Trans-PET® BioCaliburn® LH system: a large FOV small-animal PET system. Phys Med Biol. 2015;60:137–50.CrossRefPubMed
26.
Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med. 1991;32:1573–80.PubMed
27.
Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med. 1993;34:1260–6.PubMed
28.
Staelens L, Oltenfreiter R, Dumont F, Waterhouse RN, Vandenbulcke K, Blanckaert P, et al. In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studies. Nucl Med Biol. 2005;32:193–200.CrossRefPubMed
29.
Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55:408–13.PubMed
30.
Waterhouse RN, Chapman J, Izard B, Donald A, Belbin K, O’Brien JC, et al. Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Nucl Med Biol. 1997;24:587–93.CrossRefPubMed
31.
John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, Baumgold J, et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med. 1993;34:2169–75.PubMed
32.
Maffioli L, Mascheroni L, Mongioj V, Gasparini M, Baldini MT, Seregni E, et al. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med. 1994;35:1741–7.PubMed
33.
Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander BT. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008;249:836–44.CrossRefPubMed
34.
Haddad D, Garvey EM, Mihalik L, Pockaj BA, Gray RJ, Wasif N. Preoperative imaging for early-stage cutaneous melanoma: predictors, usage, and utility at a single institution. Am J Surg. 2013;206:979–86.CrossRefPubMed
35.
Kubota K, Watanabe H, Murata Y, Yukihiro M, Ito K, Morooka M, et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nucl Med Biol. 2011;38:347–51.CrossRefPubMed
Metadata
Title
Imaging malignant melanoma with 18F-5-FPN
Authors
Hongyan Feng
Xiaotian Xia
Chongjiao Li
Yiling Song
Chunxia Qin
Qingyao Liu
Yongxue Zhang
Xiaoli Lan
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3134-2

Other articles of this Issue 1/2016

European Journal of Nuclear Medicine and Molecular Imaging 1/2016 Go to the issue

Erratum

Erratum to: Difficulties in deciding whether to ablate patients with putatively “low–intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study

Original Article

Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer

Original Article

Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

Erratum

Erratum to: Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis

Original Article

Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET

Original Article

Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [11C]ABP688 PET